Identification of synergistic drug combinations with the oral HSP90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancer

C.G. Langdon (1), N. Wiedemann (2), H. Maby-El Hajjami (2), M.A. Held (1), J.T. Platt (1), D. Wang (3), G. Vuagniaux (2), M.W. Bosenberg (1), D.F. Stern (1), F. Lévy (2)

Presented at AACR 2014, San Diego, CA, USA

1. Yale University, USA
2. Debiopharm International SA, Switzerland
3. Curis Inc., USA